GMP “Pharmaceutical Inspectorate” Being Considered By FDA
Executive Summary
FDA is considering creating a dedicated force of inspectors to focus on pharmaceutical manufacturing in an effort to improve the expertise and uniformity of inspections
You may also be interested in...
Therapeutic Biologic GMP Inspections To Become “More Systems-Based”
Therapeutic biologics manufacturing compliance inspections will move toward the systems-based approach used by the Center for Drug Evaluation & Research, Office of Regulatory Affairs Regional Operations Director Deborah Ralston said
Therapeutic Biologic GMP Inspections To Become “More Systems-Based”
Therapeutic biologics manufacturing compliance inspections will move toward the systems-based approach used by the Center for Drug Evaluation & Research, Office of Regulatory Affairs Regional Operations Director Deborah Ralston said
Preapproval Inspections: Industry Urges FDA Transition To “For Cause”
FDA should consider moving to "for cause" preapproval inspections as part of its quality systems initiative, drug manufacturers told FDA at the Product Quality Research Institute/FDA conference in Washington, D.C. April 24